Enarodustat vs SSS17
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline
Enarodustat
Marketed by Shionogi and partners
NCT04027517 · Phase 3 · completed
The trial was randomized and actively controlled with 172 participants, but it was open-label and used hemoglobin, a laboratory surrogate, as its primary endpoint. Because no primary endpoint results or statistical comparison are available, the study provides limited evidence rather than demonstrating a positive or negative treatment effect.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: June 2027 · NCT07079579 (registry estimate)
Reported efficacy
Difference in mean Hb concentration levels from baseline at weeks 7-9 (Baseline and week 7-9): Mean Hb change from baseline averaged over Weeks 7-9: enarodustat +15.99 g/L (SD 9.46) vs placebo +0.14 g/L (SD 8.08); P<0.001 (met)
Result source: NCT06016036
SSS17
Developed by Shenyang Sunshine Pharmaceutical
NCT07014631 · Phase 2 · completed
The study randomized 86 participants to SSS17 or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in hemoglobin, a laboratory surrogate measure, and the comparison has not been reported, so no conclusion can yet be drawn about whether the endpoint was met.
No aligned efficacy figure on record for this race.
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Enarodustat | SSS17 |
|---|---|---|
| Kidney composite outcome | —Not posted · NCT04027517 | —Not reported |
| UACR, % change | —Not posted · NCT04027517 | —Not reported |
| eGFR slope | —Not posted · NCT04027517 | —Not reported |
| Haemoglobin, change | —Not posted · NCT04027517 | —Not reported |
Kidney composite outcome
- Enarodustat
- —Not posted · NCT04027517
- SSS17
- —Not reported
UACR, % change
- Enarodustat
- —Not posted · NCT04027517
- SSS17
- —Not reported
eGFR slope
- Enarodustat
- —Not posted · NCT04027517
- SSS17
- —Not reported
Haemoglobin, change
- Enarodustat
- —Not posted · NCT04027517
- SSS17
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SSS17: no structured comparison results are available for Chronic Kidney Disease.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Enarodustat's landscape · SSS17's landscape